No abstract available
MeSH terms
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzenesulfonates / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / metabolism
-
Carcinoma, Renal Cell / pathology
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Clinical Trials, Phase III as Topic
-
Drug Therapy, Combination
-
Humans
-
Interferons / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / metabolism
-
Kidney Neoplasms / pathology
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyridines / therapeutic use*
-
Randomized Controlled Trials as Topic
-
Sorafenib
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzenesulfonates
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Niacinamide
-
Interferons
-
Sorafenib